Design, Synthesis and Biological Studies of Tetrazole Fused olpidemimidazopyridines
New tetrazole fused imidazopyridine derivatives (12a–j) were developed to exploit their cytotoxic activity towards cancer cell lines-MCF7, A549, and MDA-MB-231, utilizing MTT reduction assay with doxorubicin as standard drug. The compounds 12 h and 12j demonstrated strong anticancer activity bearing IC50 values 1.44 µM and 1.33 µM against A549 cell line.
Reddy, B., Taneja, A. K., Tej, M. B., Sri, K. N., Tej, M. B., Vijayardhini, S., Srilaxmi, D., Tiruveedhula, S., Penumutchu, S. R., & Rao, M. V. B. (2023). Design, synthesis and biological studies of tetrazole fused imidazopyridines. Carbon Letters. https://doi.org/10.1007/s42823-023-00603-2